E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
11 nov. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be...
HeadCheck Health Announces the Appointment of New Board Member Specialized in Insurance
08 nov. 2021 07h00 HE | HeadCheck Health, Inc.
VANCOUVER, British Columbia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- HeadCheck Health, Inc. ('HeadCheck'), a leading tech-enabled provider of concussion protocol management for sports organizations,...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
21 oct. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
20 oct. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
19 oct. 2021 10h03 HE | Odyssey Group International
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) --   Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
14 oct. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
12 oct. 2021 08h00 HE | electroCore, Inc.
Third quarter 2021 revenue expected to be approximately $1.5 millionNet cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ, Oct. 12, 2021 (GLOBE...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
07 oct. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
30 sept. 2021 09h05 HE | electroCore, Inc.
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
29 sept. 2021 08h00 HE | electroCore, Inc.
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the...